RESUMO
BACKGROUND: Type 1 (Th1) and Type 2 (Th2) immunity have both been implicated in granuloma annulare (GA). To what extent these pathways contribute to clinical/histologic heterogeneity and/or distinct disease endotypes remains unexplored. METHODS: We retrospectively analyzed 30 GA biopsies with either palisaded or interstitial histology with and without eosinophils. We performed RNA in situ hybridization to assess how markers of Type 1 (interferon gamma), Type 2 (interleukin [IL]4, IL13, IL5), and Type 3 (IL17A) immunity in GA compared with canonical inflammatory disorders and whether markers correlated with histology. We analyzed another cohort of 14 patients who had multiple biopsies across anatomic space and time for individual conservation of histologic features. RESULTS: Interferon (IFN)G staining is highest in GA relative to other cytokines. Type 2 cytokine staining is less prominent, with IL4 increased in interstitial pattern cases. Eosinophils did not correlate with Type 2 markers. Patients with multiple biopsies display intrapatient variability in histology. CONCLUSION: Type 1 inflammation predominates over Type 2 inflammation in GA irrespective of histologic pattern. Distinct disease endotypes were not detected.
Assuntos
Eosinófilos , Granuloma Anular , Humanos , Estudos Retrospectivos , Granuloma Anular/patologia , Granuloma Anular/imunologia , Granuloma Anular/diagnóstico , Masculino , Feminino , Eosinófilos/patologia , Eosinófilos/imunologia , Pessoa de Meia-Idade , Biópsia , Adulto , Interferon gama , Interleucina-4 , Células Th2/imunologia , Interleucina-17/metabolismo , Interleucina-5 , Células Th1/imunologia , Idoso , Coloração e Rotulagem , Citocinas/metabolismo , Pele/patologia , Pele/imunologia , Adulto Jovem , Hibridização In SituRESUMO
BACKGROUND: Granuloma annulare (GA) is a common cutaneous inflammatory disorder characterized by macrophage accumulation and activation in skin. Its pathogenesis is poorly understood, and there are no effective treatments. The potential health implications of severe GA are unknown. OBJECTIVE: We sought to better understand GA pathogenesis and evaluate a molecularly targeted treatment approach for this disease. METHODS: We used single-cell RNA sequencing to study the immunopathogenesis of GA and also evaluated the efficacy of tofacitinib (a Janus kinase 1/3 inhibitor) in 5 patients with severe, long-standing GA in an open-label clinical trial. RESULTS: Using single-cell RNA sequencing, we found that in GA lesions IFN-γ production by CD4+ T cells is upregulated and is associated with inflammatory polarization of macrophages and fibroblasts. In particular, macrophages upregulate oncostatin M, an IL-6 family cytokine, which appears to act on fibroblasts to alter extracellular matrix production, a hallmark of GA. IL-15 and IL-21 production appears to feed back on CD4+ T cells to sustain inflammation. Treatment of 5 patients with recalcitrant GA with tofacitinib inhibited IFN-γ and oncostatin M, as well as IL-15 and IL-21, activity and resulted in clinical and histologic disease remission in 3 patients and marked improvement in the other 2. Inhibition of these effects at the molecular level paralleled the clinical improvement. Evidence of systemic inflammation is also present in some patients with severe GA and is mitigated by tofacitinib. CONCLUSIONS: The Janus kinase-signal transducer and activator of transcription pathway is activated in GA, likely in part through the activity of IFN-γ and oncostatin M, and Janus kinase inhibitors appear to be an effective treatment.
Assuntos
Citocinas/imunologia , Granuloma Anular/tratamento farmacológico , Inibidores de Janus Quinases/uso terapêutico , Piperidinas/uso terapêutico , Pirimidinas/uso terapêutico , Idoso , Linfócitos T CD4-Positivos/efeitos dos fármacos , Linfócitos T CD4-Positivos/imunologia , Fibroblastos/efeitos dos fármacos , Fibroblastos/imunologia , Granuloma Anular/genética , Granuloma Anular/imunologia , Granuloma Anular/patologia , Humanos , Inibidores de Janus Quinases/farmacologia , Macrófagos/efeitos dos fármacos , Macrófagos/imunologia , Pessoa de Meia-Idade , Piperidinas/farmacologia , Pirimidinas/farmacologia , Análise de Sequência de RNA , Pele/efeitos dos fármacos , Pele/imunologia , Pele/patologiaAssuntos
COVID-19/complicações , Granuloma Anular/diagnóstico , SARS-CoV-2/isolamento & purificação , Biópsia , COVID-19/diagnóstico , COVID-19/imunologia , COVID-19/virologia , Teste de Ácido Nucleico para COVID-19 , Feminino , Dedos , Granuloma Anular/imunologia , Granuloma Anular/patologia , Humanos , Pessoa de Meia-Idade , RNA Viral/isolamento & purificação , SARS-CoV-2/genética , SARS-CoV-2/imunologia , Pele/patologiaAssuntos
Anticorpos Monoclonais Humanizados/efeitos adversos , Granuloma Anular/diagnóstico , Idoso , Biópsia , Feminino , Granuloma Anular/induzido quimicamente , Granuloma Anular/imunologia , Granuloma Anular/patologia , Humanos , Neuromielite Óptica/tratamento farmacológico , Neuromielite Óptica/imunologia , Pele/patologiaRESUMO
BACKGROUND: Granuloma annulare (GA) is an inflammatory skin disorder. Localized GA is often self-resolving, but generalized GA is often recalcitrant to treatments. There are no targeted treatments for GA, largely due to lack of mechanistic understanding. Recently, tumor necrosis factor antagonism showed promise in GA, suggesting an underlying immune pathogenesis. OBJECTIVE: To elucidate the immune pathogenesis and identify potential therapeutic targets for GA. METHODS: Lesional and nonlesional skin biopsy samples were obtained from patients with GA and evaluated for a large array of inflammatory markers compared with inflammatory markers from normal skin of healthy individuals. RESULTS: We found differential expression of many inflammatory genes compared with normal skin. These genes were associated with T-helper (Th) cell type 1/innate immunity (tumor necrosis factor-α, interleukin [IL]-1ß, IL-12/23p40, signal transducer and activator of transcription 1, chemokine [C-X-C motif] ligand 9/10), Janus kinase signaling, and Th2 (IL-4, IL-31, chemokine (C-C motif) ligands 17 and 18; P < .05). Unexpectedly, IL-4 showed significant upregulation in GA lesional skin vs control skin (15,600-fold change). LIMITATIONS: Limited sample size. CONCLUSIONS: Our findings shed light on the inflammatory pathways of GA, supporting the notion that immune mechanisms could be driving disease, as suggested by the promising data of tumor necrosis factor-α inhibitors in GA. The significant Janus kinase and particularly Th2 signaling in GA advocates for the investigation of specific Janus kinase- and Th2- targeted drug therapy.
Assuntos
Granuloma Anular/imunologia , Janus Quinases/imunologia , Pele/imunologia , Células Th1/imunologia , Células Th2/imunologia , Biomarcadores/metabolismo , Biópsia , Feminino , Granuloma Anular/genética , Humanos , Imunidade Inata , Inflamação/genética , Inflamação/imunologia , Masculino , Pessoa de Meia-Idade , Regulação para CimaAssuntos
Granuloma Anular/diagnóstico , Hidroxicloroquina/administração & dosagem , Tuberculose Latente/diagnóstico , Pele/patologia , Gordura Subcutânea/patologia , Biópsia , Pré-Escolar , Esquema de Medicação , ELISPOT , Granuloma Anular/tratamento farmacológico , Granuloma Anular/imunologia , Granuloma Anular/patologia , Humanos , Testes de Liberação de Interferon-gama , Tuberculose Latente/complicações , Tuberculose Latente/tratamento farmacológico , Tuberculose Latente/imunologia , Masculino , Mycobacterium tuberculosis/imunologia , Mycobacterium tuberculosis/isolamento & purificação , Pele/imunologia , Gordura Subcutânea/imunologia , Resultado do TratamentoAssuntos
Síndrome de Down/complicações , Psoríase/diagnóstico , Adolescente , Biópsia , Dermatomicoses/diagnóstico , Dermatomicoses/imunologia , Dermatomicoses/patologia , Diagnóstico Diferencial , Síndrome de Down/imunologia , Feminino , Granuloma Anular/diagnóstico , Granuloma Anular/imunologia , Granuloma Anular/patologia , Humanos , Psoríase/imunologia , Psoríase/patologia , Pele/imunologia , Pele/patologia , Dermatopatias/diagnóstico , Dermatopatias/imunologia , Dermatopatias/patologiaRESUMO
Disseminated granuloma annulare (GA) is a rare granulomatous dermatitis of unknown etiology. Treatment is often challenging and lack of a uniformly effective treatment, adds to the disease morbidity. Tumor necrosis factor (TNF)-α is an important cytokine in granuloma formation and previous reports have shown improvement of disseminated GA with anti-TNF-α therapy. Nevertheless, the underlying mechanism of actions of TNF-α inhibitors in GA remains unclear. Our aim was to evaluate alterations in the inflammatory infiltrate in a patient who experienced complete clearance of GA after treatment with infliximab. A skin biopsy was obtained before and 24 weeks after treatment with infliximab 5 mg/kg at weeks 0, 2, 6, 14 and 24. Immunohistochemical stains were performed in pre- and post-treatment biopsy specimens using CD1a, CD4, CD8, CD11c, CD32, CD68, CD69, CD163, CD183 and human leukocyte antigen (HLA)-DR to characterize alterations of the infiltrates. Parallel with clinical improvement, we observed a marked decrease in myeloid (CD11c) dendritic cells, different macrophage subsets (CD68, CD32, CD163) and T cells. In addition, a marked reduction of activation markers (HLA-DR, CD69) and CD183+ (CXCR3) cells was observed in post-treatment biopsy specimens. In conclusion, the clinical improvement of disseminated GA by infliximab is paralleled by inhibition of activated myeloid dendritic cells, different macrophage subsets and type 1 T cells.
Assuntos
Células Dendríticas/efeitos dos fármacos , Fármacos Dermatológicos/farmacologia , Granuloma Anular/tratamento farmacológico , Infliximab/farmacologia , Macrófagos/efeitos dos fármacos , Idoso , Biópsia , Células Dendríticas/imunologia , Células Dendríticas/metabolismo , Fármacos Dermatológicos/uso terapêutico , Granuloma Anular/imunologia , Granuloma Anular/patologia , Humanos , Infliximab/uso terapêutico , Macrófagos/imunologia , Macrófagos/metabolismo , Masculino , Receptores CXCR3/imunologia , Receptores CXCR3/metabolismo , Pele/citologia , Pele/efeitos dos fármacos , Pele/patologia , Resultado do Tratamento , Fator de Necrose Tumoral alfa/antagonistas & inibidores , Fator de Necrose Tumoral alfa/imunologiaRESUMO
BACKGROUND: Granuloma annulare (GA), a benign inflammatory skin disease, is considered a Th1-type delayed hypersensitivity reaction. Localized GA is likely to resolve spontaneously, whereas disseminated GA (DGA) may persist for decades and can be resistant to treatment. Biologics including TNF-α inhibitors have been proposed and utilized as salvage therapy for GA and other related diseases, interstitial granulomatous dermatitis (IGD), and actinic granuloma (AG). METHODS: A systematic review was conducted using the combination of search terms "granuloma annulare," "interstitial granulomatous dermatitis," or "actinic granuloma" and either "biologics," "etanercept," "adalimumab," "infliximab," "ustekinumab," "ixekizumab," "secukinumab," "guselkumab," "golimumab," "brodalumab," "tildrakizumab," or "certolizumab" from the years 1970-2017. RESULTS: Review of the literature revealed that 79.3% of the patients with GA, IGD, or AG who had been treated with demonstrated TNF-α inhibitor therapy a clinical response. CONCLUSIONS: TNF-α inhibitor therapy has been used to treat chronic GA, IGD, and AG that involved extensive body surface areas. However, the literature is limited to case series lacking control groups. Randomized, controlled trials are required to establish evidence-based treatment of GA and related cutaneous, granulomatous conditions.
Assuntos
Produtos Biológicos/uso terapêutico , Granuloma Anular/tratamento farmacológico , Fator de Necrose Tumoral alfa/antagonistas & inibidores , Doença Crônica , Granuloma/tratamento farmacológico , Granuloma/imunologia , Granuloma Anular/imunologia , Humanos , Pele/efeitos dos fármacos , Resultado do TratamentoRESUMO
A granuloma is a form of inflammation, which predominantly consists of macrophages. It typically develops when the immune system attempts to enclose substances that are usually insoluble and cannot be eliminated to prevent the spread of these substances to the other body compartments. According to the source of the substances, granulomatous diseases can be divided into two groups: infectious and non-infectious. The mechanisms of infectious granuloma formation have been widely investigated because of its easy reproducibility in experimental models, both in vivo and in vitro. On the contrary, mechanisms of non-infectious granuloma formation have not been well investigated because of the difficulty to reproduce this formation in experimental models. In this article, we review our recent understanding of the histogenesis and pathogenesis of granuloma formation, confirmed from studies of infectious granulomas, and we present potential hypotheses of the histogenesis and pathogenesis of non-infectious granulomas based on clinical investigations.
Assuntos
Granuloma/patologia , Macrófagos/imunologia , Dermatopatias/patologia , Dermatite/imunologia , Dermatite/patologia , Granuloma/imunologia , Granuloma Anular/imunologia , Granuloma Anular/patologia , Humanos , Necrobiose Lipoídica/imunologia , Necrobiose Lipoídica/patologia , Sarcoidose/imunologia , Sarcoidose/patologia , Dermatopatias/imunologiaRESUMO
Granuloma annulare (GA) is a noninfectious granulomatous skin condition that can present with a variety of cutaneous morphologies. It is characterized by collagen degeneration, mucin deposition, and palisaded or interstitial histiocytes. Although the mechanism underlying development of GA is unknown, studies point to a cell-mediated hypersensitivity reaction to an as-yet undetermined antigen. Systemic associations with diabetes, thyroid disorders, lipid abnormalities, malignancy, and infection are described in atypical GA. Treatment is divided into localized skin-directed therapies and systemic immunomodulatory or immunosuppressive therapies. The selected treatment modality should be based on disease severity, comorbid conditions, consideration of potential side effects, and patient preference.
Assuntos
Granuloma Anular/imunologia , Interferon gama/imunologia , Interleucina-12/imunologia , Linfócitos T/imunologia , Fator de Necrose Tumoral alfa/imunologia , Antimaláricos/uso terapêutico , Complemento C3/imunologia , Diabetes Mellitus/epidemiologia , Granuloma Anular/epidemiologia , Granuloma Anular/patologia , Granuloma Anular/terapia , Humanos , Hiperlipidemias/epidemiologia , Imunoglobulina M/imunologia , Imunossupressores/uso terapêutico , Neoplasias/epidemiologia , Fotoquimioterapia , Retinoides/uso terapêutico , Pele/patologia , Tetraciclinas/uso terapêutico , Células Th1/imunologia , Doenças da Glândula Tireoide/epidemiologia , Terapia UltravioletaRESUMO
Granulomatous disorders are chronic cell-mediated immune responses histologically characterized by collections of macrophages, epithelioid cells, and multinucleated giant cells. This disease spectrum often has an infectious origin, but sometimes neither an infective agent nor an inciting antigenic stimulus can be identified. The skin may be a preferential target for these disorders, especially in the areas that have been damaged by various forms of skin injury (eg, herpetic infections, trauma, thermal or solar burns, vaccinations, tattoos). These damaged skin sites frame the new concept of an immunocompromised cutaneous district (ICD), which defines a skin area with acquired immune dysregulation that can pave the way for the local onset of opportunistic disorders, such as infections, tumors, and granulomatous disorders. Sarcoidosis, granuloma annulare (GA), and forms of granulomatous vasculitis, such as Churg-Strauss syndrome (CSS) and Wegener's granulomatosis (WG), are the most common granulomatous disorders that occur in an ICD and may share common pathogenic mechanisms. Recent studies have found clinical and pathologic overlapping features across noninfectious granulomas. Although no unifying etiology exists, the development of granulomatous processes in the ICD has often been reported and the literature contains various hypotheses to explain it: (1) overactive immune response in a previously injured region with or without loss of immune tolerance; (2) overall reduced immune response; (3) retention of an exogeneous antigen or foreign body; (4) altered neural signaling; and (5) a combination of all the aforementioned processes. T helper cells, T regulatory cells, and macrophages, as well as a number of antigenic proteins, have been identified as potential contributing factors. In addition, a genetic predisposition and an intact systemic immune system are both instrumental for the persistence of local granuloma formation in the ICD.
Assuntos
Granuloma Anular/imunologia , Hospedeiro Imunocomprometido , Sarcoidose/imunologia , Dermatopatias/imunologia , Pele/imunologia , HumanosRESUMO
BACKGROUND: Factor XIII subunit A (FXIII-A) is used as a diagnostic marker in a wide range of dermatological diseases ranging from inflammatory lesions to malignancies, although neither the cell types responsible for its expression nor the mechanism(s) resulting in its local accumulation in pathological conditions have been characterized. OBJECTIVE: In this study, we aimed to gain information on the cells showing an immunohistochemical reaction for FXIII-A and answer the question whether macrophages and/or dendritic cells are labelled for FXIII-A. METHODS: We carried out our studies on samples of granuloma annulare (GA) and necrobiosis lipoidica (NL), the prime examples for granulomatous skin lesions with a non-infectious background in which extracellular matrix remodelling is a key feature without any sign of malignant transformation. We used markers for macrophages and dendritic cells in combination with the detection of FXIII-A in double labelling immunohistochemical reactions. RESULTS: We demonstrated that FXIII-A positivity clearly distinguishes macrophages (CD163+/FXIII-A+) from dendritic cells (CD11c+/FXIII-A-) not only in the normal dermis as previously described by Zaba et al. (J Clin Invest 2007; 117: 2517-2525) but also in the pathological conditions of GA and NL. Detecting the expression of DC-SIGN/CD209 and mannose receptor molecules on FXIII-A+ macrophages we confirmed that FXIII-A is expressed in the alternatively activated macrophages. However, while DC-SIGN/CD209 was invariably expressed on FXIII-A+ cells both in normal and pathological conditions of GA/NL (98.7% vs. 93.5/96%), mannose receptor was only partially coexpressed with FXIII-A (94.8% vs. 74.7/52.2%), suggesting that FXIII-A+ macrophages do not represent a homogenous population. CONCLUSIONS: FXIII-A selectively marks macrophages and distinguishes them from dendritic cells. The presence of FXIII-A is not a disease-specific marker but indicates a possible common mechanism of macrophage activation in various dermatological diseases.
Assuntos
Células Dendríticas/classificação , Fator XIIIa/análise , Granuloma Anular/imunologia , Macrófagos/classificação , Imunofluorescência , HumanosRESUMO
BACKGROUND: Regulatory T cells (Tregs), together with tolerogenic dendritic cells (tDCs) are involved in maintaining peripheral tolerance. A recent report suggested both Tregs and tDCs may be pathogenic in granulomatous skin disorders. AIM: To examined the expression of CD39 on granuloma-composing cells and Foxp3-positive Tregs in the skin in two representative granulomatous diseases, sarcoidosis and granuloma annulare (GA). METHODS: We immunohistologically examined expression of CD39 on granuloma-composing cells and expression of Foxp3 on CD4+ or CD25+ cells in fixed sections of lesional skin from 16 patients with sarcoidosis and five patients with GA. RESULTS: The granuloma-composing cells expressed CD39 in both sarcoidosis and GA. Significant numbers of CD4+ Foxp3+ Tregs were present diffusely throughout the granulomatous tissues in sarcoidosis, whereas Tregs in GA existed only at the peripheral lesion of palisading granulomatous tissue. CONCLUSIONS: There was infiltration of increased numbers of Foxp3+ Tregs around the CD39+ granuloma-composing cells in both GA and sarcoidosis.
Assuntos
Antígenos CD/metabolismo , Apirase/metabolismo , Granuloma Anular/imunologia , Sarcoidose/imunologia , Linfócitos T Reguladores/imunologia , Linfócitos T CD4-Positivos/imunologia , Fatores de Transcrição Forkhead/imunologia , Granuloma Anular/patologia , Humanos , Imunidade Celular , Imuno-Histoquímica , Sarcoidose/patologiaAssuntos
Diabetes Mellitus Tipo 1/complicações , Granuloma Anular/complicações , Autoimunidade , Nádegas , Criança , Diabetes Mellitus Tipo 1/imunologia , Diabetes Mellitus Tipo 1/patologia , Granuloma Anular/imunologia , Granuloma Anular/patologia , Humanos , Perna (Membro) , Masculino , Pele/imunologia , Pele/patologiaRESUMO
Granuloma annulare (GA) is a reactive process in the dermis, related to degeneration of collagen. It may occur as an idiopathic phenomenon or in conjunction with a myriad of systemic conditions, including infectious disease. We report an interesting case of GA precipitated by pulmonary coccidioidomycosis.